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Abstract
Objective: The objective of this selective EBM review is to determine whether or not topical heat
patches are more effective at relieving pain associated with dysmenorrhea than OTC NSAIDs
(Ibuprofen 400 mg PO Q8h or Acetaminophen 500mg PO Q6h) in menstruating women 18 and
over.
Study Design: Review of three English-language randomized control trials (RCTs) that were
published in 2001, 2004, and 2012.
Data Sources: Three single-blinded randomized control trials that were found using PubMed
Outcome measured: Dysmenorrhea and any associated pain relief was measured using patientreported scales of NRS-10 Pain scale, 6-Point categorical scale, and patient reports of sensual,
emotional, current, and total pain.
Results: Akin et. al 2001 and 2004 studies found that topical heat patches were associated with
statistically significant greater reduction in pain associated with dysmenorrhea than oral
NSAIDs. A 2012 study by Navvabi Rigi, et al., however, showed no statistically significant
difference in pain reduction in patients that received topical heat versus an oral NSAID.
Conclusions: Some studies have shown that topical heat causes greater pain reduction than oral
NSAIDs, though the results are inconclusive among all studies. Further studies with larger
sample sizes and double blinding will be needed to determine the true effectiveness of topical
heat in treating pain associated with dysmenorrhea versus oral NSAIDs.
Key Words: Heat, dysmenorrhea
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INTRODUCTION
Dysmenorrhea is pain associated with a woman’s menstrual cycle that is believed to occur as a
result of necrosis of the endometrial layer3. This paper evaluates 3 RCTs that compare the
efficacy of topical heat patches as a treatment for dysmenorrhea against traditional OTC
NSAIDs.
Dysmenorrhea is a very common problem affecting an estimated 15.8 – 89.5% of women of
childbearing age worldwide3. Rates of dysmenorrhea are higher among adolescents, with
prevalence and severity generally decreasing with age3. Since painful menstrual cramps are such
a common problem, it is no surprise that dysmenorrhea is a leading cause of absenteeism from
work and is the most common reason for school absence in young women4. In addition to
causing a disruption in women’s education and work, dysmenorrhea takes a toll on the health
care system. It is estimated that 14-18% of young women with primary dysmenorrhea seek
primary care2.
Primary dysmenorrhea is believed to be caused by the myometrial stimulant and vasoconstrictor,
prostaglandin F2α (PGF2α)4. Traditional methods of treatment have included oral
contraceptives; prescription and over the counter nonsteroidal anti-inflammatory drugs such as
Diclofenac, Ibuprofen, Ketoprofen, mecloenamate, and naproxen; dietary supplements such as
thiamine, fish oil, pyridoxine, magnesium, and vitamin E; Exercise, and acupuncture4. In
addition to these remedies, however, topical heat has long been a home remedy for treatment of
dysmenorrhea via hot water bottles and electric heating pads. These methods, however, are
impractical for use throughout the day. With the creation of topical heat pads, it will be
beneficial to compare their efficacy against OTC NSAIDs in the treatment of dysmenorrhea due
to the side effects of chronic NSAID use 2. The traditional treatment, OTC NSAIDs are also
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known to cause GI inflammation, bleeding, rash, pruritis, tinnitus, dizziness, and renal or hepatic
complications, making the prospect of using topical heat even more appealing3.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not topical heat patches
are more effective at relieving pain associated with dysmenorrhea than OTC NSAIDs (Ibuprofen
400 mg PO Q8h or Acetaminophen 500mg PO Q6h) in menstruating women 18 and over.
METHODS
Specific selection criteria of three randomized control trials (RCTs) were used for this review.
The population studied was made of menstruating women, aged 18 and over, with a history of
dysmenorrhea. In each of the 3 RCTs a topical heat patch was used as the intervention.
Additionally, each RCT compared the pain relief provided by the heat patch against an OTC
NSAID - either Ibuprofen 400 mg Q8hr or Acetaminophen 500 mg PO Q6h. The outcome
measured in each of the RCTs was a decrease in symptoms of dysmenorrhea and any associated
pain relief.
The studies included in this review were three randomized control trials (RCTs). Keyword
searches to obtain these articles included the words “heat” and “dysmenorrhea”. Each of the
articles was published in peer-reviewed journals in English. RCTs for this review were searched
for by the author of this review via PubMed and were selected based on their relevance to the
clinical question and patient-oriented outcome. Inclusion criteria included studies that were
randomized control trials published between 1999 and the present. Studies were excluded if they
were published before 1999 or included patients less than 18 years of age. Statistics included in
these 3 RCTS included mean change in pain from baseline, p values, odds ratios, and number
needed to treat. Table 1 shows the demographics of the included studies.
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Table 1: Demographics of Included Studies
Study

Type

#
Pts

Age
(years)

Inclusion Criteria

Exclusion Criteria

W/
D

Interventions

Akin,
2001
(1)

RCT

84

21-50

Patients that are nonpregnant
women
of
menstrual age who suffer
from moderate or severe
menstrual pain for at least
4 of their last 6 menstrual
cycles, at least 18 years of
age, have a hx of pain
relief
from
OTC
analgesics
and
use
reliable
forms
of
contraception

3

Topical
heat
abdominal
patches
and
placebo pill VS
Placebo
patch
and
400
mg
ibuprofen
PO
Q6hrs

Akin,
2004
(2)

RCT

367

18-50

23

Continuous, lowlevel, topical heat
wrap
VS.
Acetaminophen
500mg PO Q6Hrs

Nawa
bi
Rigi,
2012
(3)

RCT

147

18-30

Patients
that
are
premenopausal women at
least 18 years of age with
a
medical
history,
physical, and pelvic exam
consistent with primary
dysmenorrhea,
women
must also have regular,
monthly periods over the
last 9 months with
moderate
or
greater
menstrual pain occurring
in at least 4 of their last 6
menstrual cycles as well
as a consistent use of
contraception
Patients aged 18-30 with
a hx of dysmenorrhea
within the first 2 years of
onset of menstruation
with regular menstrual
cycles, good general
health and a hx of
moderate
to
severe
dysmenorrhea

Patients that use any other
supplemental
devices
or
analgesics during the period of
the study, engage in vigorous
exercise, excessive alcohol
consumption,
or
sexual
intercourse during the 12
hours before the study and
throughout the remainder of
the study, patients with
cutaneous lesions involving
the
abdominal
wall,
microvascular
disease,
known/suspected drug or
alcohol
abuse,
known/suspected
contraindication
to
oral
ibuprofen, and patients that are
pregnant or recently pregnant
Patients
with
known
contraindication to use of
study medication or devices,
history positive for secondary
dysmenorrhea,
use
of
hormonal contraceptives of IU
for < 6 months, consistent use
of medication that could
interact with the study
medication,
devices,
or
evaluation parameters

Patients with a hx of
comorbidities
(including
cardiovascular, renal, hepatic,
pulmonary),
coagulopathy,
DM, anemia, GI bleeding,
immunological
disorder,
malignancy, psychiatric illness
requiring
therapeutic
intervention. Also, patients
with
a
hx
of
oral
contraceptives,
smoking,
pregnancy,
professional
athlete
activity,
lower
abdominal scars, BMI > 30,
and vagnitis, or recent death or
stress in the family

42

Iron
chipcontaining heat
wrap
VS
Ibuprofen 400mg
PO Q8hr PRN
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OUTCOMES MEASURED
Each of the three RCTs used patient-reported pain scales in order to determine the effectiveness
of the topical heat patch versus the NSAID. The studies, however, varied in methods of rating
patient-reported pain. Since the patients could not be blinded to which treatment they were
receiving, each of the studies was single-blinded – meaning the individuals recording data for the
study were not aware to which group each patient belonged. The two studies by Akin M, et. al
used both the 6 point categorical scale and the NRS-101 to record patient pain1,2. The 6-point
categorical scales ranges from zero to five – zero representing no pain, while five indicates
maximum pain1,2. The NRS-101 scales ranges from zero to one hundred – zero representing “not
unpleasant at all” and one hundred representing “the most unpleasant feeling possible for me.”1,2
The 2012 study by Navvabi Rigi, et. al used the short form of the McGill Pain Questionnaire,
also known as the SF-MPQ, to measure pain. SF-MPQ consists of 15 descriptors3. It has been
proven to be a reliable tool with proven validity in assessing obstetric patients and has been
previously used to assess dysmenorrhea3. Additionally, the 2012 study used visual analog scales
ranging from zero to one hundred to rate current pain and from zero to five to rate “overall pain
severity”3.
RESULTS
The 2001 study by Akin et. al was a randomized, placebo and active control “double dummy”,
parallel study1. Eighty-four women were found to be eligible for the study, with eighty one of
them completing it1. The three women who did not complete the study were lost due to their
failure to follow study protocol – “worst case” analysis was not performed1. Inclusion criteria for
this study included non-pregnant women of menstrual age who suffered from moderate to severe
menstrual pain for at least the last 4 of their 6 menstrual cycles; at least 18 years of age; history
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and physical consistent with primary dysmenorrhea; have a history of pain relief from OTC
analgesics; reliable contraception including barrier, abstinence, or sterilization1. Exclusion
criteria for this study included use of any supplemental devices or analgesics during the study
period; vigorous exercise, alcohol consumption, or sexual intercourse during the 12 hours before
the study and throughout the remainder of the study; cutaneous lesions of the abdominal wall;
microvascular disease including diabetes; known or suspected drug or alcohol abuse; known or
suspected contraindication to oral ibuprofen; pregnant or recently pregnant 1. Women were
randomly assigned to one of four groups using a computer program1. The four groups were as
follows - heated patch plus ibuprofen, heated patch plus placebo, unheated patch plus ibuprofen,
and unheated patch plus placebo1. Women were given “kidney bean-shaped ultra-thin medical
devices” to adhere to the inside of their underwear on the lower abdominal region which was
standardized between participants1. The patches supply constant heat of 38.9°C for 12 hours,
after which it was replaced with a new one 1. Women assigned to ibuprofen groups were given
400 mg ibuprofen three times a day, six hours apart 1. This review is focused on the results of
two groups – unheated patch plus ibuprofen (n=21) and heated patch plus placebo (n=20) 1. Pain
relief was recorded every two hours for two days. During the 2 day study, women receiving the
unheated patch plus placebo had a 35% incidence of complete pain reduction 1. Women who
received the experimental treatment of heated patch plus placebo had a statistically significant
incidence of complete pain relief of 70%, OR 4.3%, p = 0.015 (Table 2) 1. Women assigned to
the unheated patch and ibuprofen group, however, did not have a statistically significant
incidence of complete pain relief at only 55%, OR 2.3, p = 0.103 (Table 2) 1. These numbers
correlate to a relative benefit increase (RBI) of 0.273, an absolute benefit increase (ABI) of
0.150, and a number needed to treat (NNT) of 7 (Table 3). This study shows that the use of heat
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patches alone for treatment of pain associated with dysmenorrhea is statistically significantly
better than placebo while the use of the traditional use of ibuprofen alone is not. The study
showed that for every 7 people treated with the heat patch plus placebo, one had more pain relief
than those treated with the unheated patch plus ibuprofen. Factors that may have affected the
study include redness at the adhesion site of the patch as well as other symptoms of
dysmenorrhea including breast fullness and tenderness.

Table 2: 2001 Akin Study: Unheated Patch plus Ibuprofen vs. Heated Patch plus Placebo
Placebo
Control
Experimental
unheated
patch unheated
patch heated
patch
Treatment
plus placebo
plus Ibuprofen
plus placebo
Number of patients, N
20
21
20
Incidence of complete pain
35%
55%
70%
relief at day 2
Odds Ratio, OD
--2.3
4.3
p value
--0.103
0.015

Table 3: 2001 Akin Study: Statistical Analysis of Heated Patch plus Placebo vs. Unheated
Patch plus Ibuprofen
CER:
EER: heated
unheated
patch
plus Relative Benefit Absolute Benefit Number needed
patch
plus placebo
Increase, RBI
Increase, ABI
to treat, NNT
ibuprofen
0.55
0.70
0.273
0.15
7

The 2004 study by Akin et. was a randomized, active control, parallel, single-blind, multisite
study2. Three hundred sixty seven women were entered into the initial study with three hundred
forty four women completing the study2. Patients were lost due to violations related to dosing
compliance as well as study drop out – “worst case” analysis was not performed2. Inclusion
criteria for the study included premenopausal women of at least 18 years of age; a medical
history, physical, and pelvic exam consistent with primary dysmenorrhea; women that had
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regular, monthly periods over the last 9 months with moderate to severe menstrual pain
occurring in at least 4 of their last 6 menstrual cycles; consistent use of contraception; and
absences of a history of secondary dysmenorrhea 2. Exclusion criteria for the study included
known contraindication to use of the study medications or devices; use of hormonal
contraception or IUD for less than 6 months; consistent use of medication that could interact
with the study medication, devices, or evaluation perameters 2. Women were randomized to one
of four groups – oral acetaminophen (n = 156), active heat wrap therapy (n = 155), oral placebo
(n = 22), and inactive heat wrap (n = 24). The mean age of the women enrolled in the study was
28.8 years old2. Oral acetaminophen dosing was 500 mg twice a day, 8 hours apart2. Participants
were randomly assigned and groups were equally random based on race, daily tobacco use, age,
height, and baseline pain intensity2. The study measured pain relief using a 6 point categorical
scale at hours 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 24, and 482. This study showed that at the end point of
day 1, the heat wrap group had a statistically significant mean pain relief score (2.48 ± 0.10)
compared to the oral acetaminophen group (2.17 ± 0.10, p value = 0.015) seen in Table 42. This
indicates that at the end of the first 8 hour day, the heat wrap group had significantly less pain
than the acetaminophen group. Additionally, the heat wrap group reported less adverse events
compared the acetaminophen group, 2 versus 4, respectively (Table 5). The two adverse events
in the heat wrap group were a mild conjunctivitis and moderate application site reaction2. The
four adverse events in the acetaminophen group were moderate head ache, moderate rhinitis,
moderate respiratory infection, and severe anxiety2.
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Table 4: 2004 Akin Study: Acetaminophen vs. Heat Wrap
Control

Experimental

Treatment

Acetaminophen

Heat Wrap

Mean pain relief from baseline

2.17

2.48

standard deviation

0.1

0.1

p value

0.015

Table 5: 2004 Akin Study: Adverse Events
Control
Acetaminophen
moderate Head ache
moderate rhinitis
moderate respiratory infection
severe anxiety

Experimental
Heat Wrap
mild conjunctivitis
moderate application site reaction
-----

The 2012 study by Navvabi Rigi, et. al was a randomized control trial with blind raters 3. 186
women were assessed for eligibility in the study with 39 women being excluded for not meeting
inclusion criteria3. Inclusion criteria included age 18-30, history of dysmenorrhea within the first
2 years of onset of menstruation, regular menstrual cycles, “good” general health, and a history
of moderate to severe dysmenorrhea3. Exclusion criteria for this study included history of
cardiovascular, renal, hepatic or pulmonary comorbidities; history of oral contraceptives,
smoking, pregnancy, professional athlete activity, lower abdominal scars, BMI > 30, vaginits, or
recent death or stress in the family3. The remaining 150 women were randomly assigned to one
of two groups – ibuprofen ( n = 75) and heat patch ( n = 75) 3. Three women of the heat patch
group were lost because they did not receive the allocated intervention – worst case analysis was
not performed3. There were no statistically significant differences among the two groups in
respect to marital status, socio-economic status, BMI, or abdominal circumference3. The dose of
ibuprofen given to the women in the ibuprofen group was 400mg by mouth every 8 hours as
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needed for pain3. In this study, current severity of pain was measured on a 0-100 scale by
patients. This study shows that when “current pain” was measured at hour 8 of treatment, the
ibuprofen group had a slightly lower, though statistically insignificant, total pain score –
indicating a T score of 1.18 and a p-value of 0.24 (Table 6) 3. The authors found it important to
note that the maximum effectiveness of the heat patch is 8 hours. It is also important to note that
only 79% of the initial participants were eligible and completed the study3.
Table 6: 2012 Navvabi Rigi Study: Student T Test comparing Ibuprofen vs. Heat Patch
T Test 1.18
P
0.24
Value

DISCUSSION
This systematic review used three randomized control trials to assess the effectiveness of topical
heat in pain relief associated with dysmenorrhea compared to oral non-steroidal antiinflammatory drugs. Two of the three studies included in this review showed significantly
greater pain relief when using topical heat as compared to oral NSAIDs 1,2. One study, however,
showed no statistical significantly difference between the two treatments when measuring total
current pain at hour 83. It is important to note however, that these studies had some limitations.
The 2001 Akin et. al study included only 84 women, which is not expected to accurately
represent an entire population1. Furthermore, the 2004 Akin et. al study and the 2012 Navvabi
Rigi study only had 367 and 147 women total in each of their studies, respectively 2,3. The other
limitation of these studies is that none of the studies were double-blinded. Participants would be
aware if they were only being treated with a heat patch vs. pill3 or a heated vs. unheated patch1,2
which made double-blinding difficult. It is also important to note that prior studies have showed
that pharmacotherapy is general ineffective in treating dysmenorrhea in 20-25% of the
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population3. Also, since these RCTs studied pain, it is important to remember that individuals
have varying pain tolerances and this was not accounted for during randomization in each of the
three studies. Lastly, it is also important to remember that two of the three studied ibuprofen as
the oral NSAID of choice, while one used acetaminophen. Additionally, all three studies used
different dosing of the oral NSAIDs which could have resulted in different results among the
studies.
CONCLUSIONS
The purpose of this systematic review is to determine whether or not topical heat patches are
more effective at relieving pain associated with dysmenorrhea than OTC NSAIDs (Ibuprofen
400 mg PO Q8h or Acetaminophen 500mg PO Q6h) in menstruating women 18 and over. The
results of the three randomized control trials are inconclusive. The two studies performed by
Akin et. al showed that patients treated with topical heat patches have statistically significant
greater pain reduction that those taking oral NSAIDs1,2. A study by Navvabi Rigi et. al, however,
showed no statistically significant difference in pain relief between patient using topical heat
patches versus oral NSAID3.
Due to the high prevalence of dysmenorrhea3, low incidence of adverse event of using topical
heat patches2 and relatively low cost of heat patches3, it would be advantageous to continue with
further studies on this topic. Further studies should work to blind participants, include larger
sample sizes, and take pain tolerance into account when randomization the sample.
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